For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
44
views
19
references
 Top references
cited by
109
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      43
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2 diabetes inadequately controlled on metformin with or without a second oral glucose-lowering drug.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

          Matthew C Riddle, Julio Rosenstock, John Gerich (2003)
          To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c). In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG)
          Article 0 comments Cited 296 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

            Stephen Gough, Bruce Bode, Vincent Woo … (2014)
            A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. We aimed to compare combined insulin degludec-liraglutide (IDegLira) with its components given alone in insulin-naive patients.
            Article 0 comments Cited 141 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes.

              Louis Monnier, Gareth J Dunseath, Mandy D Owens … (2007)
              The aim of the study was to determine whether the loss of fasting and postprandial glycemic control occurs in parallel or sequentially in the evolution of type 2 diabetes. In 130 type 2 diabetic patients, 24-h glucose profiles were obtained using a continuous glucose monitoring system. The individuals with type 2 diabetes were divided into five groups according to A1C levels: 1 ( or =9%, n = 26). The glucose profiles between the groups were compared. The overall glucose concentrations for the diurnal, nocturnal, and morning periods, which represent the postprandial, fasting, and the dawn phenomenon states, respectively, were also compared. Glucose concentrations increased steadily from group 1 to 5 in a stepwise manner. The initial differences in mean glucose concentrations reaching statistical significance occurred 1) between groups 1 and 2 (6.4 vs. 7.7 mmol/l, P = 0.0004) for daytime postprandial periods, followed by differences; 2) between groups 2 and 3 (7.5 vs. 9.3 mmol/l, P = 0.0003) for the morning periods (dawn phenomenon); and finally 3) between groups 3 and 4 (6.3 vs. 8.4 mmol/l, P < 0.0001) for nocturnal fasting periods. The deterioration of glucose homeostasis in individuals with type 2 diabetes progressed from postprandial to fasting hyperglycemia following a three-step process. The first step related to the three diurnal postmeal periods considered as a whole, the second step occurred during the morning period, and the third and final step corresponded to sustained hyperglycemia over the nocturnal fasting periods. Such a description of the key stages in the evolution of type 2 diabetes may be of interest for implementing antidiabetes treatment.
              Article 0 comments Cited 118 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): Diabetes Care
                Title: Diabetes care
                Publisher: American Diabetes Association
                ISSN (Electronic): 1935-5548
                ISSN (Print): 0149-5992
                Publication date (Electronic): Nov 2016
                Volume: 39
                Issue: 11
                Affiliations
                [1 ] Dallas Diabetes Research Center at Medical City, Dallas, TX juliorosenstock@dallasdiabetes.com.
                [2 ] LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
                [3 ] Grunberger Diabetes Institute, Bloomfield Hills, MI.
                [4 ] GWT-TUD GmbH, Dresden Technical University, Dresden, Germany.
                [5 ] San Raffaele Scientific Institute, Milan, Italy.
                [6 ] Groupe Hospitalier Mutualiste Les Portes du Sud, Vénissieux, France.
                [7 ] Sanofi R&D, Beijing, China.
                [8 ] Sanofi, Bridgewater, NJ.
                [9 ] Diabetes Division, Sanofi, Frankfurt, Germany.
                [10 ] Diabetes Division, Sanofi, Paris, France.
                [11 ] Diabetes Research Centre, University of Leicester, Leicester, U.K.
                Article
                Publisher Item ID: dc16-0917
                DOI: 10.2337/dc16-0917
                PubMed ID: 27527848
                SO-VID: 0e46d145-a0a8-4a02-a90c-291ed1484a53
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content43

                See all similar

                Cited by109

                See all cited by

                Most referenced authors350

                See all reference authors